PharmD_Rodriguez said:

The liver data is among the strongest non-weight findings in the class.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I would resist the confidence. Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

The figures, for anyone assembling their own picture. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

LipidDoc_ATL said:

Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

Adding the part of the answer the thread has not reached. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Following on from stefan_berlin — and this may be the naive question:

Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?

Closing the loop on my own question.

Late follow-up. I did not do what was suggested, I did something adjacent, and it worked; posting the difference in case it matters to somebody.